Setting sail: Atara raises $38.5m for Amgen spin-outs
This article was originally published in Scrip
Atara Biotherapeutics raised $38.5m in a Series B venture capital round to launch its three drug development ships – the Nina, Pinta and Santa Maria – with drug candidates from Amgen for protein energy wasting associated with end-stage renal disease and ovarian cancer.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.